Combined use of active ingredients enables treatment of forms that are difficult to treat – healing practice

Improved treatment of triple negative breast cancer

A combination of drugs already approved for other types of cancer appears to be an effective treatment forms of breast cancer that are particularly difficult to treat to allow.

In a new study involving experts from Louisiana State University were using a mouse model and the tissue of women with triple negative breast cancer (triple-negative breast cancer) examined a total of 133 drugs already approved by the FDA in the USA, including the drugs ceritinib and enzalutamide.

The results were published in the English-language journal “Molecular Cancer“ published.

Risk of triple negative breast cancer

Triple negative breast cancer often affects younger women. Women of African and Hispanic descent and women affected by deleterious germline mutations in breast cancer susceptibility genes are also more likely to develop this form of cancer, the researchers explain.

This aggressive type of breast cancer does 15 to 20 percent of all breast cancers out.

What is ceritinib?

The drug Ceritinib According to the team, is a so-called low molecular weight tyrosine kinase inhibitor. Ceritinib is usually used in treating people with non-small cell lung cancer used.

What is enzalutamide?

at Enzalutamide On the other hand, it is a low molecular weight drug that targets the androgen receptor and treatment of prostate cancer is used, the researchers explain.

Combined treatment of triple negative breast cancer

Will both drugs combinedthis seems effective for treating chemoresistant triple negative breast cancer to be. This form of cancer lacks estrogen receptors, progesterone receptors and the human epidermal growth factor receptor 2 (HER2).

Androgen receptors as a target of cancer treatment

A subtype of this cancer, which twelve to 55 percent of triple-negative breast cancer tumors constitutes, has androgen receptors (AR). Because androgen receptors stimulate tumor cell progression in estrogen receptor-negative breast cancer, they represent a target in therapy for triple-negative breast cancer, the team said.

Many affected women are resistant to paclitaxel

A Problem in treating triple negative breast cancer is, according to the experts, that a significant number of sick women have a Resistance to paclitaxel developed.

Paclitaxel is a drug approved by the FDA as a chemotherapy drug for triple negative breast cancer. Therefore, new therapeutic approaches are needed. The FDA is the US Food and Drug Administration.

What did combined treatment achieve?

Ultimately, the researchers found in their study that Ceritinib efficiently inhibits the growth of triple-negative androgen receptor breast cancer cells. To improve response to the drug, they also chose enzalutamide, an androgen receptor antagonist.

We have developed a novel combination strategy of enzalutamide and ceritinib to treat AR+ TNBC tumors through dual blockade of androgen-dependent and androgen-independent AR signaling‘ explains the author of the study Dr. Suresh Alahari in a press release.

Inhibited growth of AR+ TNBC cells

It was found that a combination of ceritinib and enzalutamide robust inhibitory effect on the growth of AR+ TNBC cells brings with it. A combination of paclitaxel and ceritinib has also been studied and found to have beneficial effects.

The combination of paclitaxel and ceritinib showed dramatic inhibition of tumor growth compared to either agent alone. All agents used in our study are FDA approved, so the proposed combination therapy is likely to be used in the clinic as well“, adds Dr. Alahari added. (as)

Author and source information

This text corresponds to the specifications of medical specialist literature, medical guidelines and current studies and has been checked by medical professionals.

Sources:

  • Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, et al.: Ceritinib is a novel triple negative breast cancer therapeutic agent; in: Molecular Cancer (veröffentlicht 29.06.2022), Molecular Cancer
  • Louisiana State University Health Sciences Center: LSU Health Research Suggests Novel Combination Therapy for Triple-Negative Breast Cancer (veröffentlicht 29.06.2022), Louisiana State University Health Sciences Center

Important NOTE:
This article contains general advice only and should not be used for self-diagnosis or treatment. He can not substitute a visit at the doctor.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.